Katrin Gysel
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti L. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. JTO Clin Res Rep 2024; 5:100735.
Oct 15, 2024Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
Oct 15, 2024JTO Clin Res Rep 2024; 5:100735
Schmid Sabine, Holer Lisa, Gysel Katrin, Koster Kira-Lee, Rothschild Sacha I, Boos Laura A, Frehner Lorenz, Cardoso Almeida Sabine, Britschgi Christian, Metaxas Yannis, Mark Michael, Froesch Patrizia, Janthur Wolf-Dieter, Allemann Anna, Waibel Christine, Von der Mühll-Schill Catherine, Früh Martin, Mauti Laetitia A
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. J Cancer Res Clin Oncol 2024; 150:84.
Feb 8, 2024Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Feb 8, 2024J Cancer Res Clin Oncol 2024; 150:84
Peres Tobias, Aeppli Stefanie, Fischer Stefanie, Gysel Katrin, Rothermundt Christian
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer 2024; 200:113600.
Feb 5, 2024First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Feb 5, 2024Eur J Cancer 2024; 200:113600
Mark Michael, Froesch Patrizia, Gysel Katrin, Rothschild Sacha I, Addeo Alfredo, Ackermann Christoph Jakob, Chiquet Sabrina, Schneider Martina, Ribi Karin, Maranta Angela Fischer, Bastian Sara, von Moos Roger, Jörger Markus, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)